🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Genmab A/S (CPH:GMAB)
Denmark flag Denmark · Delayed Price · Currency is DKK
3,491.00
-6.00 (-0.17%)
Nov 20, 2026, 11:24 AM CET

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 220.96 billion. The enterprise value is 242.86 billion.

Market Cap220.96B
Enterprise Value 242.86B

Important Dates

The last earnings date was Thursday, November 5, 2026.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Genmab has 63.30 million shares outstanding. The number of shares has decreased by -1.08% in one year.

Current Share Class 63.30M
Shares Outstanding 63.30M
Shares Change (YoY) -1.08%
Shares Change (QoQ) +0.58%
Owned by Insiders (%) 1.10%
Owned by Institutions (%) 60.95%
Float 58.96M

Valuation Ratios

The trailing PE ratio is 45.37 and the forward PE ratio is 32.12. Genmab's PEG ratio is 1.50.

PE Ratio 45.37
Forward PE 32.12
PS Ratio 7.83
PB Ratio 5.31
P/TBV Ratio n/a
P/FCF Ratio 39.52
P/OCF Ratio 38.44
PEG Ratio 1.50
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.88, with an EV/FCF ratio of 43.43.

EV / Earnings 50.70
EV / Sales 8.60
EV / EBITDA 26.88
EV / EBIT 28.09
EV / FCF 43.43

Financial Position

The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.82.

Current Ratio 2.45
Quick Ratio 2.43
Debt / Equity 0.82
Debt / EBITDA 3.78
Debt / FCF 6.11
Interest Coverage 3.49

Financial Efficiency

Return on equity (ROE) is 12.07% and return on invested capital (ROIC) is 12.73%.

Return on Equity (ROE) 12.07%
Return on Assets (ROA) 8.24%
Return on Invested Capital (ROIC) 12.73%
Return on Capital Employed (ROCE) 11.31%
Weighted Average Cost of Capital (WACC) 7.06%
Revenue Per Employee 8.71M
Profits Per Employee 1.48M
Employee Count3,244
Asset Turnover 0.43
Inventory Turnover 14.32

Taxes

In the past 12 months, Genmab has paid 322.46 million in taxes.

Income Tax 322.46M
Effective Tax Rate 6.30%

Stock Price Statistics

The stock price has increased by +76.05% in the last 52 weeks. The beta is 0.52, so Genmab's price volatility has been lower than the market average.

Beta (5Y) 0.52
52-Week Price Change +76.05%
50-Day Moving Average 2,850.84
200-Day Moving Average 2,082.41
Relative Strength Index (RSI) 60.01
Average Volume (20 Days) 231,982

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 28.27 billion and earned 4.80 billion in profits. Earnings per share was 76.95.

Revenue28.27B
Gross Profit 26.20B
Operating Income 8.66B
Pretax Income 5.12B
Net Income 4.80B
EBITDA 8.92B
EBIT 8.66B
Earnings Per Share (EPS) 76.95
Full Income Statement

Balance Sheet

The company has 12.31 billion in cash and 34.21 billion in debt, with a net cash position of -21.89 billion or -345.91 per share.

Cash & Cash Equivalents 12.31B
Total Debt 34.21B
Net Cash -21.89B
Net Cash Per Share -345.91
Equity (Book Value) 41.68B
Book Value Per Share 658.45
Working Capital 12.43B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.76 billion and capital expenditures -157.94 million, giving a free cash flow of 5.60 billion.

Operating Cash Flow 5.76B
Capital Expenditures -157.94M
Depreciation & Amortization 272.59M
Net Borrowing 35.44B
Free Cash Flow 5.60B
FCF Per Share 88.48
Full Cash Flow Statement

Margins

Gross margin is 92.67%, with operating and profit margins of 30.63% and 16.97%.

Gross Margin 92.67%
Operating Margin 30.63%
Pretax Margin 18.11%
Profit Margin 16.97%
EBITDA Margin 31.56%
EBIT Margin 30.63%
FCF Margin 19.13%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 1.08%
Shareholder Yield 1.08%
Earnings Yield 2.20%
FCF Yield 2.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Analyst Forecast

The average price target for Genmab is 4,195.23, which is 20.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target 4,195.23
Price Target Difference 20.17%
Analyst Consensus Strong Buy
Analyst Count 16
Revenue Growth Forecast (3Y) 26.11%
EPS Growth Forecast (3Y) 22.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Genmab has an Altman Z-Score of 3.02 and a Piotroski F-Score of 4.

Altman Z-Score 3.02
Piotroski F-Score 4